LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, discusses strategies to address underrepresentation in phase III psoriasis trials. She also talks about Takeda's partnerships with community stakeholders like Inside Edge, Black Health Matters, and Hispanic Communication Global Network to help improve engagement, address operational barriers by incorporating multicultural imagery, and prioritize sites with diverse patient demographics. She also explains how they've enhanced investigator diversity through educational sessions and multilingual toolkits, and how Takeda aims to expand these efforts globally.
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
May 15th 2025Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.